Scholars Central

Rapid communicationPublished 30 Jun 2025

Immunotherapy Revolutionizing Gynecologic Cancers: Progress and Challenges

Authors: Dr. Natasha Evans

Memorial Sloan Kettering Cancer Center, USA

Insights in Gynecologic Oncology

Volume 10 · Issue 3 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immunotherapy, especially immune checkpoint inhibitors (ICIs), is rapidly transforming gynecologic oncology, demonstrating efficacy in advanced ovarian, cervical, and endometrial cancers. Pembrolizumab has become a standard of care for specific advanced cervical cancers and dMMR/MSI-H endometrial cancers. Challenges include biomarker identification, resistance mechanisms, and tumor microenvironment modulation. Novel targets, gut microbiome influence, and CAR T-cell therapy are under investigation. Safe management of immune-related adverse events is essential. Personalized immunotherapy strategies are a key focus.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Insights in Gynecologic Oncology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInsights in Gynecologic Oncology
  • SubjectOncology & Cancer
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Dr. Natasha Evans”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels